GSK bets on pioneering cancer therapy with Adaptimmune deal

LONDON (Reuters) - GlaxoSmithKline said it has licensed the rights to Adaptimmune's pioneering T-cell therapy program to boost its pipeline in oncology, one of four areas its has prioritized for research and development.